INTRODUCTION
Only a few decades ago, Kaposi's sarcoma was considered to be a malignant cutaneous vascular neoplasm that developed most often on the lower extremities of older men of Jewish and Mediterranean heritage". More recently, Kaposi's sarcoma has reached epidemic proportions as one of the for~most components of the acquired immunodeficiency syndrome (AIDS)2. The cuta~eous lesions in patients with AIDS often occur at Sides other than the lower extremities and may be solitary, few, many, or innumerable. In this setting, the proliferation of the neoplastic endothelial cells of eit?er vasc,!lar~r lymphatic vessels, is almost cer~amly multifocal . The disease may run a remarkably indolent course for many months with new lesions co~tinuing.to co~e, or rapidly progressive from the time of dlagn?sls.
The widespread localization often seen in patients with AIDS-associated Kaposi's sarcoma preferably requires systemic treatme~t. Althoug~,often rapidl.y progressive, AIDS-ass.oclat~d KapOSI s .sar~o~a IS seldom a life-threatening disease. The indications for treatment are predominantly the disfiguring and stigmatic nature of the disease, a~d. at later stages, pain, or oedema due to lymphatic involvement. Established troublesome localizations are oropharyngeal lesions, obstructive intestinal lesions and pulmonary lesions. In this review, both single agent interferon-a and the combination of interferon-a and zidovudine will be discussed. In order to weigh its benefits, the other~reatment modalities such as chemotherapy and radiotherapy will also be discussed.
SINGLE-AGENT INTERFERON-ALPHA
Interferons have been investigated for use in the treatment of AIDS-associated Kaposi's sarcoma since the recognition of AIDS in 1981. The. immu~o modulating, antiproliferative, and antiretroviral Correspondence to: R de Wit MDPhD, Rotterdam Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands activity of interferons made them attractive to study for the therapy of Kaposi's sarcoma in this setting.
A number of reports have now confirm~d interferon-a's activity for Kaposi's sarcoma m patients with AIDS4-11. The initial studies of recombinant (interferon-o-Za and interferon-o-Zb) or natural interferon-a were conducted in heterogeneous populations of patients with Kapo~i's sarcoma. These trials were designed to determine whether low doses (1-3 million units), or high doses (20-50 million units and even higher doses), of interferon-a given daily or every other day were more effective in antitumour effect, or immune modulation, or both. A clear dose response of tumour regression has been demo~st!atedi~thes 2e studies with high doses >20 million umts/m, resulting in major (complete and partial) response rates of 20-40%.
No comparative studies have been ,!ndert~ento determine whether daily treatment IS superior to treatment thrice weekly, or 5 day weekly schedules, and whether there is rationale for a high dose daily induction schedule followed by thrice weekly maintenance schedules. There are also no comparative data for doses of 20 million units/m-and higher doses. At present, treatment regim~ns.with interferon-o-Za commonly employed are daily intramuscular or subcutaneous administration of doses of 36 million units, and interferon-a-2b therapy is recommended at 30 million units/m-three times weekly, based on schedules that had proved ef~ca~l and therefore were chosen in subsequent studies . Since the majority of patients nowadays will also receive zidovudine treatment it is not to be expected that sufficient numbers of patients can be accrued in randomized studies with different single-agent high-dose interferon-a schedules,~nd therefore~t will not be possible to assess which schedule IS superior.
. Analysis of responders compared WIth nonresponders to therapy have revealed th~t sev~ral factors are associated with a poor response including extensive disease, constitutional symptoms such as fever, night sweats, and weight loss, a number of CD4 + cells at the initiation of interferon treatment of less than 200 cells/!-tl, and either a current or history of a prior opportunistic infection 4,7,13-15. Thus, response to interferon is correlated with relative preservation of the immune system. Subsequent studies have selectively treated only those patients likely to respond, that is, those without opportunistic infections and CD4 + cell numbers of 200/!-tl and more and have improved the tumour response rate to an average of 50%; those patients with greater than or equal to 200 CD4 + cells are almost fourfold more likely to respond than those with fewer CD4+ cells.
About one-third of the responses have been biopsy-confirmed complete responses. Median demonstration of response have varied between studies, and are in the range of 12 and even 24 months for complete responders, and between 6 and 12 months for partial responders4,7,8,11,13.
In addition to its anti-Kaposi's sarcoma activities, interferon-a has been shown to suppress HIV replication 10,11,16,17. In two studies, patients with CD4 + cells > 200 per !-tl not only exhibited the best anti-tumour response but some patients also had increases in CD4 + cells, decreases in HIV p24 antigen, and persistently negative cultures for HIV10,l1. Significant and durable decrease of HIV p24 antigens have been found in patients whose tumours responded to treatment, and p24 antigen levels remained decreased or undetectable for many months after cessation of interferon-a therapy in cases of a complete tumour remission. Such improvements in the number of CD4+ cells during treatment and durable decreases in p24 antigen and decreases in the frequency of viral isolation may have a role in slowing the progression of HIV diseasel". In addition, it has been noted that tumour response is associated with a low incidence of opportunistic infections and prolonged survival, although interpretation of such observations in uncontrolled studies is problematicv-l-V. Though suggestive, they do not define whether treatment affects the natural history of the disease. Because zidovudine at present is standard treatment in patients with later stages of HIV-disease, including Kaposi's sarcoma, placebo controlled studies with single-agent interferon-a, which may define a possible alteration of disease course, are highly unlikely to be achievable. However, there has been one randomized, placebo controlled study with interferon-a in patients with asymptomatic HIV infection; during treatment with interferon-a 35 million units daily none of 17 patients developed AIDS, compared with 5 of 17 patients in the placebo group (P=0.02)17. While receiving interferon-a, 7 patients (41%) became HIV culture negative, and during the treatment period, CD4 + lymphocyte percentages were subtained at or above the baseline level in patients receiving interferon-a and declined lightly in patients receiving placebo. Thus, interferon-ce, when administered to Kaposi's sarcoma patients early in the course of their HIV disease, may have anti-HIV, as well as anti-Kaposi's sarcoma activity, and the optimal role of interferon in the management of HIV disease needs further elucidation, but this will be hampered by presently available concomitant antiretroviral treatment.
In general, treatment with high dose human recombinant interferon-a is well tolerated in a third of patients, and influenza-like symptoms can easily be managed by co-administration of paracetamol in another third of patients. Toxicity appears to be less pronounced than is observed in patients who are being treated with high dose interferon-a for renal cell carcinoma or melanoma, without apparent explanation for this phenomenon. In a third of patients, treatment has to be interrupted, or doses have to be reduced due to chronic symptoms such as fatigue and mental status changes. However, significant acute side effects requiring cessation of therapy are uncommon 4-15.
ZIDOVUDINE
At present zidovudine has become the main and only generally prescribed antiretroviral treatment for patients with AIDS18. It has been demonstrated that zidovudine prolongs survival, decreased opportunistic infections and improved the number of CD4 + cells in comparison to placebo treated groups19-22. Recently zidovudine usage has expanded from patients with full blown AIDS to use in HIV-positive asymptomatic patients; such use has demonstrated a reduction in the progression of the disease-'.
Zidovudine has been administered to patients with AIDS-associated Kaposi's sarcoma with minimal response. Two phase II clinical studies have shown that zidovudine is not an effective agent for the treatment of AIDS-associated Kaposi's sarcoma 24 ,25.
COMBINED INTERFERON-a AND ZIDOVUDINE
Because the commonest cause of death in patients with AIDS and Kaposi's sarcoma is opportunistic infection and not Kaposi's sarcoma, a major concern is the effect of any anti-tumour therapy on the activity of the underlying HIV infection. Although the precise mechanisms of interferon-a's anti Kaposi's sarcoma activity has not been elucidated, an association was recently found between clinical tumour response, decrease in HIV p24 antigen and increase in CD4 + cells during treatment, thereby suggesting the existence of a relationship between tumour response and antiretroviral. act~vity and immunomodulating effects 10,11. Combination of the antiretroviral agent, zidovudine, with interferon-a, has a synergistic antiviral effect in vitro 26 and has led to pilot studies of this combination. Preliminary reports on these phase I studies have shown that the combination is feasible 27-29, although interferon-a 10-20 million units and zidovudine 600 mg daily appeared to be the maximum tolerable doses in 50% of the patients, because of the development of severe neutropenia. Presently several phase II studies have been perfo~med and show somewhat conflicting results, which may partly be explained by duration of pre,:ious zidovudine treatment and drug sch~duhng: In a phase II study consisting of 21 patIents with AIDS-associated Kaposi's sarcoma, ll~terfero.n-a 9-18 million units daily was added to zidovudine-". Only one of 20 evaluable patients achieved a partial response at 8 weeks that lasted for 3 months. However, median duration of zidovudine at entry to the study was 5 months (range 2-24) and the median number of CD4+ cells at the start o~interferon-a treatment was 100/Itl, and only 7 patients had an initial cell count of 200/Itl or~)Ver. Toxicity consisted mainly of complaints of fatigue that prevented escalation of interferon-a to 18~il!ion units in the majority of cases. MyelotoXlCl~was found to be mild, and neutropenia that necessitated dose modification was seen in only a few cases.
By initial simultaneous use of interferon-a and idovudine, however, response rates can be Increased, even in the presence of low CD4 + counts-", and a second study with combined treatment has also shown considerably better esponse rates 32. However, in the latter study Interferon-a was given in high doses during the initial weeks, and thereafter doses were reduced or co~bined use with zidovudine. Such high dose induction treatment~ay have induced a response that was further Improved by maintenance treatme~t33. Although 11 of 26 patients (42%) had achieved a response during this combined tre~tment, only one achieved a complete response, which appears to be less than is observed with high-dose single agent interferon-a. In some patients p24 antigen levels were reduced during treat~ent: In agreeme~t with previous phase I studIe~, .I~thes~. studies neutropenia was the dose limiting tOXICIty. These studies do not reveal whether interferon-a could account for the anti-retrovir~l~~d a.ntitumour .effects. However, given the. variability in populations of patients, dosing regimens. and underlying level of immunodeficiency, retrospective comparisons are unreliable and prospective analysis is required. It has recently been reported that there is increased in vitro resistance to zidovudine in HIV isolates from patients receiving long-term zidovudine treatmenr'". Further studies with initial simultaneous use of interferon-a and zidovudine are warranted, especially in randomized comparison with highdose single agent interferon-a, but the addition of interferon-a to long-term zidovudine treatment should be regarded as ineffective-". At present, it is not clear whether patients with progressive Kaposi's sarcoma during zidovudine treatment, who still have CD4+ cells of 200/ltl or over, may benefit from single-agent high-dose interferon-a after cessation of zidovudine. The optimal treatment of this particular subgroup of patients requires further study. Combination chemotherapy has not been shown to be consistently superior to single-agent treatment. Volberding remarked ' none of the single-agent regim~ns or combinations has proven remarkably supenor to the others, for what one gains in overall efficacy, it tends to lose in toxicity and vice versa's'. Multiagent regimens have shown incidence of opportunistic infections of up to 60%, and therefore may exaggerate other HIV-associated complica~ions42. Although combining antiretroviral age.nts With chemotherapy would seem logical, the maJ?r dose li?1iting. toxicity of the only presently available antiretroviral agent zidovudine is also myelosuppression, and combining zidovudine with che?1ot~erapycould. lead to increased myelotoxicity which interferes WIth administration of effective doses of both zi~ovudine and the chemotherapy.
CHEMOTHERAPY

Therapeutic modalities such as cytotoxic chemo-
As yet, the possible value of the addition of haemopoetic growth factors like GM-CSF (granulocyte-macro~hage co~ony stimulating factor), G-CSF, and/or interleukin (IL)-3, to cytotoxic chemotherapy has to be determined.
RADIOTHERAPY
Radiation therapy has been an accepted form of treatment for classic Kaposi's sarcoma 42.45. This disease is known to have marked radiosensitivity responding to doses well below the tolerance of normal surrounding tissue. Results of radiotherapy for AIDS-associated Kaposi's sarcoma has shown -----------------------more or less comparable radiosensitivity46-SS. While several authors have reported good results with fractionated irradiation up to total doses of 1400-3000 cGy, others have advocated single doses of 800-1000cGy. Many reports however, do not supply data on the duration of the observed responses. The results of one study with adequate follow-up indicated that single 800 cGy fraction radiations resulted in good palliation for a short time; 23 of 36 irradiation treatments with a followup of more than 4 months showed progression of tumour within that time, and the palliative effect of the radiotherapy outlasted the survival of the patient in only 4 treated areas in 4 patients".
Furthermore, patients with AIDS-associated Kaposi's sarcoma are often more sensitive to the toxicities associated with radiation therapy such as mucositis, desquamation, hyperpigmentation, and salivary gland suppression'<. Residual pigmentation or tattooing may occur at irradiated sites and there is a high incidence of residual tumour following treatment SO,S3.
Extensive field techniques will increase morbi~i~, and immunosuppression as a result of myelotoXlClty of such irradiation, and should be reserved for situations where other therapeutic options have failed or are not possible.
INDICATIONS FOR USE OF INTERFERoN-a IN PATIENTS WITH AIDS ASSOCIATED KAPOSI'S SARCOMA; OVERALL CONCLUSIONS
At present, for patients who present with J(t:l~OSi's sarcoma as the initial manifestation of AID~nd. tudies, but at present response rates appett.hlgl), comparable to that observed With.single-a~e~fCateq dose interferon-a, and two studies have l(fjpJ 1l'l.<\y that patients with less than 2~CD4 + cel1~t' lo~~, also benefit. The addition of mterferon-a ,ifessl\>t erm zidovudine in the presence of proP Kaposi's sarcoma should be regarded as ineffective. Single agent zidovudine should also be regarded as ineffective for patients with Kaposi's sarcoma as the initial manifestation of AIDS. Treatment with chemotherapy results in short-lived responses, considerable toxicity, especially consisting of further myelosuppression and thereby accelerating HIV associated opportunistic infections. Due to the brief duration of responses with chemotherapy, patients with Kaposi's sarcoma as the initial manifestation of AIDS usually outlive the possible cytotoxic regimens. Radiotherapy may result only in local palliation, and the majority of cases relapse. 
